HBOX Therapies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $4.2M

Overview

HBOX Therapies is a German medical device startup developing the MiRA system, a novel extracorporeal respiratory support device for acute respiratory failure. The technology integrates three proprietary innovations—an advanced artificial lung, an augmented gas management system, and a novel blood pump—to enable efficient gas exchange with reduced blood damage and device complexity. Founded in 2021 by a team with deep expertise in cardiovascular engineering from RWTH Aachen, the company is in the pre-clinical/development stage, targeting a significant unmet need in intensive care. HBOX aims to improve patient outcomes and reduce ICU burden by providing a safer alternative to invasive mechanical ventilation.

Acute Respiratory FailureCritical Care

Technology Platform

Proprietary extracorporeal gas exchange platform integrating three core innovations: an advanced artificial lung designed for minimal blood contact and high efficiency, an augmented hyperbaric gas management system for enhanced gas transfer, and a novel blood pump engineered to minimize hemolysis at mid-flow rates.

Funding History

1

Total raised:$4.2M

Seed$4.2MHigh-Tech GründerfondsMay 15, 2022

Opportunities

The large and growing global incidence of acute respiratory failure, combined with the clinical limitations and high mortality of invasive mechanical ventilation, creates a significant unmet need.

HBOX's compact, potentially safer, and more user-friendly MiRA system could enable earlier intervention and expand ECMO therapy to a broader range of ICU settings, capturing a meaningful share of the expanding ECMO market.

Risk Factors

Key risks include failure to successfully integrate and validate novel technologies, inability to demonstrate superior safety/efficacy in future clinical trials, challenges in obtaining regulatory approvals, and intense competition from large, established medical device companies with dominant market positions and extensive clinical support networks.

Competitive Landscape

HBOX competes in the ECMO/ECLS market, which is dominated by large, diversified medtech players like Getinge (Maquet), LivaNova, and Medtronic. Its differentiation strategy is based on miniaturization, enhanced biocompatibility to reduce complications, and a focus on the specific needs of respiratory failure (vs. cardiac support). It may also face competition from other startups and academic groups developing next-generation artificial lungs.

More companies in Diagnostics & Precision Medicine →More companies in Germany →